Scientific Advisors

Ethan Burstein is Senior Director of Biosciences at ACADIA Pharmaceuticals Inc., where he leads drug discovery pharmacology and is responsible for advancement of preclinical leads into IND-track development.  Dr. Burstein has published over 70 peer-reviewed papers on the molecular pharmacology of G-protein coupled receptors and discovery of small molecule receptor ligands, and is one of the inventors of ACADIA's R-SAT® high-throughput screening technology.  Prior to ACADIA, Dr. Burstein was a research fellow at the University of Vermont where he received a National Research Service Award Fellowship to study the structural basis of receptor/G-protein signaling.  Dr. Burstein received his PhD in Toxicology at the University of Rochester.

Prof. Burstein has been a faculty member of the Department of Biochemistry & Molecular Pharmacology at The University of Massachusetts Medical School since 1977. His research activities have centered on the structure and function of natural and synthetic cannabinoids and their mechanism of action. His research led to the discovery of the principal route of metabolism of THC, from which he demonstrated that terminal carboxylic acid metabolites of THC are non-psychoactive, yet retain their activity as analgesic and anti-inflammatory agents. This resulted in the design and discovery of ajulemic acid (RESUNAB), a novel non-psychotropic cannabinoid drug under development by Corbus Pharmaceuticals, Inc. for the treatment of inflammation and fibrotic disease. More recently, he discovered a new family of lipid signaling molecules called lipoamino acids. Earlier in his career, Dr. Burstein was a Senior Scientist at The Worcester Foundation for Experimental Biology where, in addition to his studies on cannabinoids, he worked in the areas of steroids and prostaglandins biochemistry. Dr. Burstein received his doctoral degree at Wayne State University, a master's degree at Brandeis University and a bachelor's degree at MIT, all in the field of chemistry. He was a Postdoctoral Fellow in the department of Prof. Efraim Katchalski at The Weitzman Institute in Israel.

Dr. Chmiel received his M.D. and M.P.H. in Epidemiology, from the University of Michigan in 1991. He worked as a resident in Pediatrics in Children's Memorial Hospital in Chicago until 1994. Dr. Chmiel then joined the Pediatrics Pulmonology group at Case Western Reserve as a fellow from 1995 to 1998, where he was promoted to Instructor and then Assistant Professor of Pediatrics in 2001. In 2008, he was promoted to Associate Professor. He became Fellowship Program Director in 2001, the Associate Director of the LeRoy W. Matthews Cystic Fibrosis Center Center in 2004, and the Director of Clinical Affairs in 2007.

Daniel E Furst, M.D., is the Carl M Pearson Professor of Medicine at the University of California Los Angeles (UCLA) Medical Center, David Geffen School of Medicine, Division of Rheumatology. He earned his medical degree from Johns Hopkins University, where he also completed his internship and residency. After serving as Assistant Professor of Medicine/Rheumatology at the UCLA Medical Center and as Associate Professor of Internal Medicine/Rheumatology at the University of Iowa Carver College of Medicine, he became Clinical Professor in the Department of Medicine, Division of Rheumatology and Connective Tissue Research at the University of Medicine and Dentistry of New Jersey. He later served as Director of Clinical Research Programs and the Arthritis Clinical Research Unit at the Virginia Mason Medical Center in Seattle, WA. He has served on a number of national committees, and was a fellow in the American College of Rheumatology and The American Society of Clinical Pharmacology and Therapeutics. He has also been a member of the Arthritis Advisory Committee for the U.S. Food and Drug Administration. He has served on the editorial boards of Inpharma, Clinical Drug Investigation, Drugs, The Journal of Clinical Rheumatology, and The Journal of Rheumatology. Additionally, he is an editorial reviewer for professional publications including Arthritis & Rheumatism, The New England Journal of Medicine, Journal of Clinical Investigation, Pharmacotherapy, and the Annals of the Rheumatic Diseases. His research interests include the clinical pharmacology of anti-rheumatic drugs and biologics, and the pathophysiology and treatment of systemic sclerosis.

Dr. Michael R. Knowles is a Professor of Pulmonary and Critical Care medicine at the University of North Carolina. He has over three decades of clinical research experience that spans across the disciplines of biology, physiology, and design of clinical trials in both the academic and private sectors. He is currently the head of two large multicenter studies: 1) Genetic Modifiers of Disease phenotype (severity) in cystic fibrosis lung and liver disease, which also includes a recently formed International Consortium doing a whole genome scan; and 2) a Consortium with 8 sites in North America to study rare genetic disorders of mucociliary clearance.

Charles N. Serhan, Ph.D., is the first Endowed Distinguished Scientist at Brigham and Women’s Hospital (BWH) and since 1995 has served as Director of the Center for Experimental Therapeutics and Reperfusion Injury (CET&RI) at BWH. He is a full Professor of Anaesthesia at Harvard Medical School, is affiliated with its Department of Biological Chemistry and Molecular Pharmacology, and is also the Simon Gelman Professor of Anesthesia, Perioperative and Pain Medicine (Biochemistry & Molecular Pharmacology) at Harvard Medical School and Professor of Oral Medicine, Infection and Immunity at Harvard School of Dental Medicine. Dr. Serhan is a leading authority in inflammatory resolution and was the first to identify the role of anti-inflammatory cellular mediators such as resolvins and lipoxins in the pro-inflammatory pathway. He serves as the Director and Principal Investigator of the Serhan Laboratory at CET&RI and as the program director of a federally supported National Institutes of Health Program Project grant on the Resolution Mechanisms in Acute Inflammation: Resolution Pharmacology. He is also Principal Investigator on the NIH research grant entitled, Blood Cell Lipoxygenase Products: Formation and Action, funded since 1987 and honored with a MERIT Award. Dr. Serhan earned his Bachelor's degree in biochemistry from Stony Brook University New York, and his doctorate in Experimental Pathology and Medical Sciences from New York University School of Medicine. He completed his post-doctoral training in Physiological Chemistry at the Karolinska Institute Medical University with Professor Bengt Samuelsson, the 1982 Nobel Laureate in Medicine, and later received an honorary degree from Harvard University.

Robert B. Zurier, M.D., has been Professor of Medicine at the University of Massachusetts Medical School in Worcester since 1991, and was Chief of Rheumatology there until 2007. From 1980 to 1991 he was Professor of Medicine and Chief of Rheumatology at the University of Pennsylvania School of Medicine in Philadelphia. Dr. Zurier graduated from the University of Texas Southwestern Medical School in Dallas, trained in Internal Medicine at Boston City Hospital, then practiced general internal medicine in Holden, Massachusetts, for three years before training in clinical and research rheumatology at NYU-Bellevue Medical Center in New York City. Dr. Zurier's clinical, research, and teaching accomplishments have been recognized by election to the American Society of Clinical Investigation and the Interurban Clinical Club (President, 1987), inclusion in Who's Who In America and Best Doctors in America, designation as Master of the American College of Rheumatology, and bestowal of the Physician Recognition Award by the Arthritis Foundation, Massachusetts Chapter, in addition to the receipt of his Guggenheim Fellowship.